Vascular calcification (VC) is a major cause of mortality in patients with
chronic kidney disease (CKD). While elevations in serum
phosphorus contribute to VC, we provide evidence here for a major role of oxidative stress (OS) in VC pathogenesis without an apparent increase in serum
phosphorus in early CKD. In a rat model for stage 5 CKD (CKD5), we observed 1) robust increases of VC and OS, 2) significant reductions of smooth muscle 22 alpha (SM22α) and
calponin, and 3) upregulations in Runt-related
transcription factor 2 (RUNX2) and
collagen I in vascular smooth muscle cells (VSMCs). Inhibition of OS using
MnTMPyP dramatically reduced these events without normalization of
hyperphosphatemia. In CKD5 patients with VC (n = 11) but not in those without VC (n = 13), OS was significantly elevated. While the serum levels of
calcium and
phosphate were not altered in the animal model for early stage CKD (ECKD), OS, VC, SM22α,
calponin, RUNX2,
collagen I and
NADPH oxidase 1 (NOX1) in VSMCs were all significantly changed. More importantly, serum (5%) derived from patients with ECKD (n = 30) or CKD5 (n = 30) induced SM22α and
calponin downregulation, and RUNX2,
collagen I, NOX1 upregulation along with a robust elevation of OS and
calcium deposition in primary rat VSMCs. These alterations were all reduced by
MnTMPyP,
ML171 (a NOX1 inhibitor), and
U0126 (an inhibitor of Erk signaling). Collectively, we provide a comprehensive set of evidence supporting an important role of OS in promoting VC development in CKD patients (particularly in those with ECKD); this was at least in part through induction of osteoblastic transition in VSMCs which may involve the Erk singling. Our research thus suggests that reductions in OS may prevent VC in CKD patients.